Cartesian Therapeutics/$RNAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Ticker
$RNAC
Sector
Primary listing
Employees
75
Headquarters
RNAC Metrics
BasicAdvanced
$173M
-
-$5.02
0.23
-
Price and volume
Market cap
$173M
Beta
0.23
52-week high
$16.79
52-week low
$5.98
Average daily volume
234K
Financial strength
Current ratio
8.655
Quick ratio
8.452
Long term debt to equity
-6.753
Total debt to equity
-10.041
Profitability
EBITDA (TTM)
-83.746
Gross margin (TTM)
-1,974.87%
Net profit margin (TTM)
-4,658.63%
Operating margin (TTM)
-3,099.93%
Effective tax rate (TTM)
6.59%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-14.82%
Return on equity (TTM)
195.88%
Valuation
Price to revenue (TTM)
60.453
Price to book
-1.34
Price to tangible book (TTM)
-0.63
Price to free cash flow (TTM)
-2.13
Free cash flow yield (TTM)
-46.96%
Free cash flow per share (TTM)
-3.057
Growth
Revenue change (TTM)
-92.81%
Earnings per share change (TTM)
12.02%
3-year revenue growth (CAGR)
-70.66%
3-year earnings per share growth (CAGR)
18.97%
What the Analysts think about RNAC
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
RNAC Financial Performance
Revenues and expenses
RNAC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cartesian Therapeutics stock?
Cartesian Therapeutics (RNAC) has a market cap of $173M as of March 21, 2026.
What is the P/E ratio for Cartesian Therapeutics stock?
The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of March 21, 2026.
Does Cartesian Therapeutics stock pay dividends?
No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of March 21, 2026.
When is the next Cartesian Therapeutics dividend payment date?
Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.